

Stephen J Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6400119/publications.pdf>

Version: 2024-02-01

76
papers

17,399
citations

147726

31
h-index

79644

73
g-index

77
all docs

77
docs citations

77
times ranked

27119
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	13.9	11,472
2	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	13.9	1,090
3	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	13.9	709
4	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016, 353, 1129-1132.	6.0	461
5	Vaccine protection against Zika virus from Brazil. <i>Nature</i> , 2016, 536, 474-478.	13.7	460
6	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	13.9	314
7	Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. <i>Nature</i> , 2018, 557, 719-723.	13.7	213
8	A review of Dengvaxia®: development to deployment. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2295-2314.	1.4	206
9	Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009, 81, 825-833.	0.6	186
10	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. <i>Lancet</i> , The, 2018, 391, 563-571.	6.3	165
11	Assessment of US Healthcare Personnel Attitudes Towards Coronavirus Disease 2019 (COVID-19) Vaccination in a Large University Healthcare System. <i>Clinical Infectious Diseases</i> , 2021, 73, 1776-1783.	2.9	163
12	Natural History of Plasma Leakage in Dengue Hemorrhagic Fever. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 283-290.	1.1	141
13	Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006487.	2.1	129
14	Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. <i>Hum Vaccin</i> , 2009, 5, 33-40.	2.4	110
15	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	108
16	Critical issues in dengue vaccine development. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 442-450.	1.3	101
17	Zika virus infection in immunocompetent pregnant mice causes fetal damage and placental pathology in the absence of fetal infection. <i>PLoS Pathogens</i> , 2018, 14, e1006994.	2.1	83
18	Immune correlates of protection for dengue: State of the art and research agenda. <i>Vaccine</i> , 2017, 35, 4659-4669.	1.7	81

#	ARTICLE	IF	CITATIONS
19	Dengue Epidemiology: Virus Epidemiology, Ecology, And Emergence. <i>Advances in Virus Research</i> , 2003, 61, 235-289.	0.9	80
20	Prospects for a Zika Virus Vaccine. <i>Immunity</i> , 2017, 46, 176-182.	6.6	79
21	Zika vaccines and therapeutics: landscape analysis and challenges ahead. <i>BMC Medicine</i> , 2018, 16, 84.	2.3	70
22	Fast-Track Zika Vaccine Development – Is It Possible?. <i>New England Journal of Medicine</i> , 2016, 375, 1212-1216.	13.9	53
23	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. <i>Vaccine</i> , 2018, 36, 3411-3417.	1.7	52
24	Space-time analysis of hospitalised dengue patients in rural Thailand reveals important temporal intervals in the pattern of dengue virus transmission. <i>Tropical Medicine and International Health</i> , 2012, 17, 1076-1085.	1.0	51
25	Clinical review of delafloxacin: a novel anionic fluoroquinolone. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1439-1451.	1.3	47
26	Current issues in dengue vaccination. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 429-434.	1.3	40
27	The Emergence of Zika Virus. <i>Annals of Internal Medicine</i> , 2016, 165, 175.	2.0	39
28	Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1379-1391.	1.3	39
29	Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 119-128.	0.6	38
30	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1061-1070.	4.6	36
31	Dengue human infection model. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1587-1590.	1.4	34
32	Trials and Tribulations on the Path to Developing a Dengue Vaccine. <i>American Journal of Preventive Medicine</i> , 2015, 49, S334-S344.	1.6	34
33	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. <i>Vaccine</i> , 2022, 40, 1483-1492.	1.7	32
34	Developing a dengue vaccine: progress and future challenges. <i>Annals of the New York Academy of Sciences</i> , 2014, 1323, 140-159.	1.8	31
35	Development of standard clinical endpoints for use in dengue interventional trials. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006497.	1.3	29
36	Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. <i>Vaccine</i> , 2009, 27, 355-368.	1.7	27

#	ARTICLE	IF	CITATIONS
37	Healthcare Personnel (HCP) Attitudes About Coronavirus Disease 2019 (COVID-19) Vaccination After Emergency Use Authorization. <i>Clinical Infectious Diseases</i> , 2022, 75, e814-e821.	2.9	27
38	Improving Dengue Virus Capture Rates in Humans and Vectors in Kamphaeng Phet Province, Thailand, Using an Enhanced Spatiotemporal Surveillance Strategy. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 24-32.	0.6	26
39	Dengue vaccine: Global development update. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2020, 38, 178-185.	0.2	26
40	Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural DENV infection. <i>EBioMedicine</i> , 2020, 54, 102733.	2.7	25
41	Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections. <i>PLoS Pathogens</i> , 2021, 17, e1009240.	2.1	23
42	Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006975.	1.3	21
43	A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain. <i>Journal of Infectious Diseases</i> , 2021, 223, 258-267.	1.9	21
44	State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. <i>Journal of Medical Case Reports</i> , 2016, 10, 233.	0.4	19
45	U.S. Service Member Deployment in Response to the Ebola Crisis: The Psychological Perspective. <i>Military Medicine</i> , 2018, 183, e171-e178.	0.4	17
46	Assessing the role of multiple mechanisms increasing the age of dengue cases in Thailand. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2115790119.	3.3	16
47	The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e333-e338.	4.6	15
48	Zika Virus Vaccines – A Full Field and Looking for the Closers. <i>New England Journal of Medicine</i> , 2017, 376, 1883-1886.	13.9	14
49	Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets. <i>Npj Vaccines</i> , 2022, 7, 9.	2.9	13
50	An Innovative, Prospective, Hybrid Cohort-Cluster Study Design to Characterize Dengue Virus Transmission in Multigenerational Households in Kamphaeng Phet, Thailand. <i>American Journal of Epidemiology</i> , 2020, 189, 648-659.	1.6	12
51	Quarantine and the U.S. military response to the Ebola crisis: soldier health and attitudes. <i>Public Health</i> , 2018, 155, 95-98.	1.4	11
52	Zika vaccine pre-clinical and clinical data review with perspectives on the future development. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2524-2536.	1.4	11
53	Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 640190.	2.2	10
54	Effect of Antimalarial Drugs on the Immune Response to Intramuscular Rabies Vaccination Using a Postexposure Prophylaxis Regimen. <i>Journal of Infectious Diseases</i> , 2020, 221, 927-933.	1.9	8

#	ARTICLE	IF	CITATIONS
55	Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity. <i>Viruses</i> , 2021, 13, 916.	1.5	7
56	Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 777672.	2.2	7
57	Simultaneous analysis of antigen-specific B and T cells after SARS-CoV-2 infection and vaccination. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 474-482.	1.1	7
58	Challenges of Vaccine Development for Zika Virus. <i>Viral Immunology</i> , 2018, 31, 117-123.	0.6	6
59	The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States. <i>Journal of Infectious Diseases</i> , 2020, 221, 1057-1069.	1.9	6
60	Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2020, 221, 1494-1498.	1.9	6
61	Finding the Signal Among the Noise in the Serologic Diagnosis of Flavivirus Infections. <i>Journal of Infectious Diseases</i> , 2018, 218, 516-518.	1.9	5
62	Encouraging results but questions remain for dengue vaccine. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 125-126.	4.6	5
63	Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology. <i>BMC Medical Research Methodology</i> , 2018, 18, 134.	1.4	5
64	Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand. <i>PLoS Pathogens</i> , 2022, 18, e1010500.	2.1	5
65	Dengue illness index—a tool to characterize the subjective dengue illness experience. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006593.	1.3	4
66	When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?. <i>Vaccines</i> , 2020, 8, 174.	2.1	3
67	Determining the Impact of the Opioid Crisis on a Tertiary-Care Hospital in Central New York to Identify Critical Areas of Intervention in the Local Community. <i>Journal of Addiction</i> , 2020, 2020, 1-7.	0.9	3
68	Key Findings and Comparisons From Analogous Case-Cluster Studies for Dengue Virus Infection Conducted in Machala, Ecuador, and Kamphaeng Phet, Thailand. <i>Frontiers in Public Health</i> , 2020, 8, 2.	1.3	2
69	Correlation between reported dengue illness history and seropositivity in rural Thailand. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009459.	1.3	2
70	Entomological Risk Assessment for Dengue Virus Transmission during 2016–2020 in Kamphaeng Phet, Thailand. <i>Pathogens</i> , 2021, 10, 1234.	1.2	2
71	Impact of a pharmacist-facilitated, evidence-based bundle initiative on <i>Staphylococcus aureus</i> bacteremia management. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115535.	0.8	2
72	Systemic Cancer Therapy Does Not Significantly Impact Early Vaccine-Elicited SARS-CoV-2 Immunity in Patients with Solid Tumors. <i>Vaccines</i> , 2022, 10, 738.	2.1	2

#	ARTICLE	IF	CITATIONS
73	Impact of a pharmacist-driven azithromycin de-escalation initiative for community-acquired pneumonia. JACCP Journal of the American College of Clinical Pharmacy, 2020, , .	0.5	0
74	66. Impact of a Pharmacist-Driven Azithromycin De-escalation Protocol for Community-Acquired Pneumonia. Open Forum Infectious Diseases, 2020, 7, S52-S52.	0.4	0
75	67. Impact of a Pharmacist-Driven Collaborative Initiative on Staphylococcus aureus Bacteremia Management. Open Forum Infectious Diseases, 2020, 7, S52-S53.	0.4	0
76	187. Vancomycin Plus Ceftaroline Salvage Therapy for Persistent Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. Open Forum Infectious Diseases, 2021, 8, S201-S202.	0.4	0